Michael Vasconcelles - 04 Jun 2026 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Reporting relationship: Director
Issuer ticker: KURA
Reported as of: 04 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Jun 2026, 18:30:14 UTC
Prior SEC filing: 23 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Teresa Bair, Attorney-in-fact for Michael Vasconcelles

Key filing fact

Michael Vasconcelles filed Form 4 for Kura Oncology, Inc. (KURA) on 04 Jun 2026.

Key facts

This page summarizes Michael Vasconcelles's Form 4 filing for Kura Oncology, Inc. (KURA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Jun 2026, 18:30.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001734755 Primary reporting owner

Relationship: Director
Address: C/O KURA ONCOLOGY, INC., 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO
Signature: /s/ Teresa Bair, Attorney-in-fact for Michael Vasconcelles
Signature date: 04 Jun 2026

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KURA transaction Derivative

Award

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

This option vests in full on the one year anniversary of the date of grant.